论文部分内容阅读
酮替芬(ketotifen)是70年代中期研制出的预防哮喘药物,能抑制肥大细胞和白细胞释放介质,尤其对慢反应物(SRS-A)抑制作用明显。在体内可预防由SRS-A诱发的支气管痉挛,能拮抗钙离子对平滑肌的作用,并对组织胺受体起到阻滞作用。临床试验表明对不同诱因所致哮喘,均有一定预防作用,长期服用时,各类哮喘有效率能达93%。传统的治疗哮喘药物不外乎3大类:支气管扩张剂、糖皮质激素以及预防哮喘发作的药物。色甘酸钠自60年代问世以来,作为唯一的预防性药物达十余年之久,直至70年代中期,又研制出酮替芬这一新的药物。
Ketotifen is the anti-asthma drug developed in the mid-1970s and inhibits the release of mast cells and leukocytes, especially for the slow-acting agent (SRS-A). Bronchospasm induced by SRS-A can be prevented in vivo, antagonizing the effect of calcium ion on smooth muscle and blocking the histamine receptor. Clinical trials show that different causes of asthma, have a preventive effect, long-term use, the effective rate of all types of asthma can reach 93%. The traditional treatment of asthma drugs are nothing more than three categories: bronchodilators, glucocorticoids and the prevention of asthma attacks drugs. Since the advent of the 60’s, cromolyn has been the only preventive drug for over a decade, and until the mid-1970s, a new drug, ketotifen, was developed.